New combo shot targets stomach cancer belly fluid
NCT ID NCT06759064
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether injecting two drugs directly into the belly can help control fluid buildup (ascites) caused by stomach cancer. The drugs are sintilimab, which helps the immune system fight cancer, and zoledronic acid, which may slow cancer growth. The trial involves 24 adults with advanced stomach cancer and aims to find a safe dose and see if it shrinks the fluid.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sintilimab (immune checkpoint inhibitor) plus zoledronic acid
- What this could lead to
- If it works, this could offer a new way to control malignant ascites in gastric cancer, potentially improving comfort and survival.
- What could go wrong
- This is an early phase I/II trial with only 24 participants, so results may not apply broadly. Side effects from the drug combination could be serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASCITES, MALIGNANT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Qilu Hospital of Shandong University
RECRUITINGJinan, Shandong, 250012, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.